David Izhaky, Ph.D., is a biotech executive with extensive scientific and management experience in building and leading large teams, achieving key milestones in drug development, clinical studies, regulatory approval, and business transactions. He is the co-founder of BOKO Therapeutics, an immuno-oncology company, and has recently co-founded EMIT, a new longevity company with the aim of extending healthy lifespan. David holds a Ph.D. in Structural Biology from the Weizmann Institute and served as a scientist for several years at the University of California, Berkeley, and the Howard Hughes Medical Institute. He also served as a team leader in IDF’s top unit 81 lab.